Codelivery of CCR7 Ligands as Molecular Adjuvants Enhances the Protective Immune Response against Herpes Simplex Virus Type 1

Journal of Virology

Volumn 77, Issue 23, 2003, Pages 12742-12752

  Toka, Felix N ^a,b   Gierynska, Malgorzata ^b   Rouse, Barry T ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BETA CHEMOKINE; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; HERPES SIMPLEX VIRUS GB PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; LIGAND; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PLASMID DNA; SECONDARY LYMPHOID TISSUE CHEMOKINE; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENITAL SYSTEM; HERPES SIMPLEX VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MEMORY; LYMPHOCYTE COUNT; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NOSE MUCOSA; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

ANIMALS; ANTIBODIES, VIRAL; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPESVIRUS 1, HUMAN; IMMUNITY, MUCOSAL; INTERFERON TYPE II; LIGANDS; LUNG; MICE; MICE, INBRED C57BL; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0242409175     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.23.12742-12752.2003     Document Type: Article

References (41)

1. Badovinac, V. P., and J. T. Harty. 2003. Memory lanes. Nat. Immunol. 4:212-213.
2. Constant, S. L., J. L. Brogdon, D. A. Piggott, C. A. Herrick, I. Visintin, N. H. Ruddle, and K. Bottomly. 2002. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J. Clin. Investig. 110:1441-1448.
3. Cyster, J. G. 1999. Chemokines and cell migration in secondary lymphoid organs. Science 286:2098-2102.
4. + T cell response to a model antigen. J. Immunol. 169:1-4.
5. Dodge, I. L., M. W. Carr, M. Cernadas, and M. B. Brenner. 2003. IL-6 production by pulmonary dendritic cells impedes Th1 immune responses. J. Immunol. 170:4457-4464.
6. Edwards, S., and C. Carne. 1998. Oral sex and the transmission of viral STIs. Sex. Transm. Infect. 74:6-10.
7. Eo, S. K., M. Gierynska, A. A. Kamar, and B. T. Rouse. 2001. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J. Immunol. 166:5473-5479.
8. + T cell responses by effects on dendritic cells. J. Immunol. 167:3592-3599.
9. Eo, S. K., S. Lee, U. Kumaraguru, and B. T. Rouse. 2001. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine 19:4685-4693.
10. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23-33.
11. Gallichan, W. S., and K. L. Rosenthal. 1996. Effects of the estrous cycle on local humoral immune responses and protection of intranasally immunized female mice against herpes simplex virus type 2 infection in the genital tract. Virology 224:487-497.
12. Gallichan, W. S., and K. L. Rosenthal. 1998. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization. J. Infect. Dis. 177:1155-1161.
13. Gallichan, W. S., R. N. Woolstencroft, T. Guarasci, M. J. McCluskie, H. L. Davis, and K. L. Rosenthal. 2001. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166:3451-3457.
14. Gierynska, M., U. Kumaraguru, S. K. Eo, S. Lee, A. Krieg, and B. T. Rouse. 2002. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J. Virol. 76:6568-6576.
15. + T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 82:845-853.
16. Hiroi, T., M. Yanagita, N. Ohta, G. Sakaue, and H. Kiyono. 2000. IL-15 and IL-15 receptor selectively regulate differentiation of common mucosal immune system-independent B-1 cells for IgA responses. J. Immunol. 165: 4329-4337.
17. Jones, H. P., L. M. Hodge, K. Fujihashi, H. Kiyono, J. R. McGhee, and J. W. Simecka. 2001. The pulmonary environment promotes Th2 cell responses after nasal-pulmonary immunization with antigen alone, but Th1 responses are induced during instances of intense immune stimulation. J. Immunol. 167:4518-4526.
18. Kaushic, C., A. A. Ashkar, L. A. Reid, and K. L. Rosenthal. 2003. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J. Virol. 77:4558-4565.
19. Knaup, B., S. Schunemann, and M. H. Wolff. 2000. Subclinical reactivation of herpes simplex virus type 1 in the oral cavity. Oral Microbiol. Immunol. 15:281-283.
20. Koelle, D. M., and A. Wald. 2000. Herpes simplex virus: the importance of asymptomatic shedding. J. Antimicrob. Chemother. 45:1-8.
21. Kuklin, N., M. Daheshia, K. Karem, E. Manickan, and B. Rouse. 1997. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol. 71:3138-3145.
22. + T-cell responses to herpes simplex virus. J. Virol. 74:5709-5711.
23. Legge, K. L., and T. J. Braciale. 2003. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 18:265-277.
24. Mahalingam, S., K. Clark, K. I. Matthaei, and P. S. Foster. 2001. Antiviral potential of chemokines. Bioessays 23:428-435.
25. + T lymphocytes. J. Immunol. 155:259-265.
26. Meseda, C. A., K. L. Elkins, M. J. Merchlinsky, and J. P. Weir. 2002. Prime-boost immunization with DNA and modified vaccinia virus Ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J. Infect. Dis. 186:1065-1073.
27. Milligan, G. N., and D. I. Bernstein. 1995. Analysis of herpes simplex virus-specific T cells in the murine female genital tract following genital infection with herpes simplex virus type 2. Virology 212:481-489.
28. Milligan, G. N., D. I. Bernstein, and N. Bourne. 1998. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:6093-6100.
29. Morrison, L. A., and D. M. Knipe. 1997. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology 239:315-326.
30. Parr, E. L., and M. B. Parr. 1999. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology 98:639-645.
31. Parr, M. B., and E. L. Parr. 1998. Mucosal immunity to herpes simplex virus type 2 infection in the mouse vagina is impaired by in vivo depletion of T lymphocytes. J. Virol. 72:2677-2685.
32. Price, D. A., P. Klenerman, B. L. Booth, R. E. Phillips, and A. K. Sewell. 1999. Cytotoxic T lymphocytes, chemokines and antiviral immunity. Immunol. Today 20:212-216.
33. SangKon, O., J. Berzofsky, D. Burke, T. Waldmann, and L. Perera. 2003. Coadministration of HIV vaccine vector with vaccinia virus expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100:3392-3397.
34. Somani, J., S. Lonial, H. Rosenthal, S. Resnick, I. Kakhniashvili, and E. K. Waller. 2002. A randomized, placebo-controlled trial of subcutaneous administration of GM-CSF as a vaccine adjuvant: effect on cellular and humoral immune responses. Vaccine 21:221-230.
35. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, and G. Dubin. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
36. Stritzke, J., T. Zunkel, J. Steinmann, N. Schmitz, L. Uharek, and M. Zeis. 2003. Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. Br. J. Haematol. 120:27-35.
37. Weninger, W., H. S. Carlsen, M. Goodarzi, F. Moazed, M. A. Crowley, E. S. Baekkevold, L. L. Cavanagh, and U. H. von Andrian. 2003. Naive T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J. Immunol. 170:4638-4648.
38. Wherry, E. J., V. Teichgraber, T. C. Becker, D. Masopust, S. M. Kaech, R. Antia, U. H. Von Andrian, and R. Ahmed. 2003. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4:225-234.
39. Wierzbicki, A., I. Kiszka, H. Kaneko, D. Kmieciak, T. J. Wasik, J. Gzyl, Y. Kaneko, and D. Kozbor. 2002. Immunization strategies to augment oral vaccination with DNA and viral vectors expressing HIV envelope glycoprotein. Vaccine 20:1295-1307.
40. Woodberry, T., J. Gardner, S. L. Elliott, S. Leyrer, D. M. Purdie, P. Chaplin, and A. Suhrbier. 2003. Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias. J. Immunol. 170:2599-2604.
41. Wu, H. Y., and M. W. Russell. 1997. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res. 16:187-201.